No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

Target·Modality

Indication

Stage

Deal Value

(USD Mn)

1

6/3

Eli Lilly

QurAlis Corporation

Antisense Oligonucleotide
(QRL-204)

Protein Unc-13 Homolog A (UNC13A)

amyotrophic lateral

sclerosis,

frontotemporal

dementia

Preclinical

622

2

6/3

Debiopharm

Genome & Co

Monoclonal Antibody

Conjugated (GENA-111)

n/d
being developed based on GNOCLE

platform and Multilink technology

Unspecified Cancer

Preclinical

431

3

6/3

Merck

Biolojic Design

Monoclonal Antibody

n/d
being developed based on Artificial

Intelligence (AI)-driven discovery platform

Unspecified Cancer
Unspecified

Immunological

Disorders

Discovery

375.3

4

6/13

AbbVie

FutureGen

Biopharmaceutical

(Beijing)

Engineered monoclonal antibody
(FGM-701)

TNF-like cytokine 1A (TL1A)

Autoimmune

disorders,

inflammatory bowel

disease

Preclinical

1710

5

6/14

Takeda Pharmaceutical

Ascentage Pharma

Group International

Small molecule
(olverembatinib, Oral route)

 Bcr-Abl tyrosine kinase

Chronic Myelocytic

 Leukemia (Marketed)
CR syndrome, Renal

carcinoma, ALL, AML,

CML, GIST (pipeline)

Marketed

1300

6

6/17

Navigator Medicines

IMBiologics

Bispecific antibody
(IMB-101)

OX40L, TNF-α

autoimmune

disorders

Phase I

940

7

6/18

Roche

Ascidian Therapeutics

Gene Therapy
DNA-Based Genome Editing

n/d

unspecified

neurological diseases

Discovery

1842

8

6/18

Day One

Biopharmaceuticals

MabCare

Therapeutics

Monoclonal Antibody

Conjugated
(DAY-301)

DNA Topoisomerase I,

Inactive Tyrosine Protein Kinase 7

Solid tumor

IND/CTA Filed

1207

9

6/18

Sanofi

Belharra Therapeutics

Small molecule (unclarified)

n/d

Unspecified

Immunological

Disorders

Discovery

740

10

6/20

Evommune

Aprilbio

Fusion Protein
(APBR-3)

Interleukin 18

autoimmune

disorders

Phase I

490

11

6/21

Melodia

Therapeutics

Alivexis

Small molecule
(MDI-0151)

Cathepsin C

chronic inflammation

diseases

Preclinical

275

12

6/27

AbbVie

Nxera Pharma

NxWave platform

novel G protein-coupled receptor

(GPCR)

neurological disease

Discovery

1250

No.

Date

Acquires

Issuer

주요 파이프라인

금액
(USD Mn)

1

6/6

GSK

Elsie Biotechnologies

(RNA Therapeutics Discovery Platform)

Type : Antisense RNAi Oligonucleotide

Indication : unspecified

Stage : Discovery

50

2

6/26

Novo Nordisk

2Seventy Bio

(Gene Therapy for Hemophilia A)

Type : Gene Therapy

Target : n/d

Indication : Hemophilia A (Factor VIII Deficiency)

Stage : Preclinical

40

3

6/27

AbbVie

Celsius Therapeutics

(CEL-383) Type : Monoclonal Antibody

Target : Triggering Receptor Expressed On Myeloid Cells 1 (TREM1)

Indication : Inflammatory Bowel Disease

Stage : Phase I

250

4

6/27

Sanofi

Vigil Neuroscience

(iluzanebart) Type : Monoclonal antibody

Target : Triggering Receptor Expressed On Myeloid Cells 2 (TREM2)

Indication : Alzheimer's Disease

Stage : Phase III

40